BCL2L1 and lung carcinoma: The combinational efficacy of YHO-1701 was abolished by BCL-XL overexpression (Fig. 4g, h), demonstrating that BCL-XL influences STAT3-mediated adaptive survival and that its downregulation is necessary for inducing apoptosis in adaptive ALK-rearranged lung cancer cells and eradicating residual tumors.